0000000000049920

AUTHOR

Carlos Ezquer

showing 4 related works from this author

Optimal doses of caspofungin during continuous venovenous hemodiafiltration in critically ill patients

2017

0301 basic medicineContinuous renal replacement therapymedicine.medical_specialtyLetterCritical Illness030106 microbiologyHemodiafiltrationCritical Care and Intensive Care MedicineEchinocandinsLipopeptides03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCaspofunginHumansMedicineIntensive care medicinebusiness.industryCritically illlcsh:Medical emergencies. Critical care. Intensive care. First aid030208 emergency & critical care medicinelcsh:RC86-88.9Invasive candidiasisContinuous venovenous hemodiafiltrationAcute Kidney Injurymedicine.diseaseInvasive candidiasisRenal Replacement TherapychemistryAdsorptionCaspofunginbusinessCritical Care
researchProduct

Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: some nuances

2020

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentCEFTOLOZANE/TAZOBACTAMMEDLINElcsh:Medical emergencies. Critical care. Intensive care. First aidlcsh:RC86-88.9Critical Care and Intensive Care MedicineTazobactammedicineRenal replacement therapyIntensive care medicinebusinessmedicine.drugCritical Care
researchProduct

Pharmacokinetics of anidulafungin during venovenous extracorporeal membrane oxygenation

2016

Echinocandins are currently considered the first-line treatment for invasive candidiasis (IC) in the intensive care unit (ICU) [1, 2]. However, extracorporeal membrane oxygenation (ECMO), a rescue therapy used in patients with severe acute respiratory distress syndrome (ARDS) [3], could alter the pharmacokinetics of certain drugs [4]. We prescribed anidulafungin for suspected IC in a patient with severe ARDS on ECMO and measured the plasma concentrations of the drug using high-performance liquid chromatography (HPLC).

0301 basic medicineDrugARDSLettermedia_common.quotation_subjectmedicine.medical_treatment030106 microbiologyCritical Care and Intensive Care Medicinelaw.invention03 medical and health sciencesEchinocandins0302 clinical medicinePharmacokineticsRescue therapylawHemofiltrationExtracorporeal membrane oxygenationMedicine030212 general & internal medicinemedia_commonExtracorporeal membrane oxygenationAcute respiratory distress syndromebusiness.industrymedicine.diseaseIntensive care unitAnesthesiaAnidulafunginbusinessmedicine.drugCritical Care
researchProduct

Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies

2019

Ceftolozane-tazobactam (C/T), a novel fifth-generation cephalosporin/β-lactamase inhibitor combination active against multidrug-resistant (MDR) Pseudomonas aeruginosa, is currently approved by the U.S. Food and Drug Administration (FDA) to treat complicated intra-abdominal and urinary tract

Adultmedicine.medical_specialtymedicine.drug_classCritical IllnessUrinary systemCephalosporinHemodiafiltrationMicrobial Sensitivity TestsOff-label usemedicine.disease_causeExtracorporealPharmacokineticspolycyclic compoundsmedicineHumansPseudomonas InfectionsPharmacology (medical)Intensive care medicineLetter to the EditorPharmacologyCritically illbusiness.industryPseudomonas aeruginosaPrecursor Cell Lymphoblastic Leukemia-Lymphomabacterial infections and mycosesAnti-Bacterial AgentsCephalosporinsInfectious DiseasesPseudomonas aeruginosaFemaleCeftolozanebusinessAntimicrobial Agents and Chemotherapy
researchProduct